A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
This Annual Report on Form 10-K contains forward-looking statements regarding future events and the future results of Charles River Laboratories International, Inc. that are based on our current expectations, estimates, forecasts and projections about the industries in which we operate and the beliefs and assumptions of our management. Words such as “expect,” “anticipate,” “target,” “goal,” “project,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “likely,” “may,” “designed,” “would,” “future,” “can,” “could” and other similar expressions, which are predictions of, indicate future events and trends or which do not relate to historical matters are intended to identify such forward-looking statements. These statements are based on our current expectations and beliefs and involve a number of risks, uncertainties and assumptions that are difficult to predict.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 4.0B | 4.0B | 4.0B | 4.1B | 4.0B | 3.5B |
| Net Income | -144M | -144M | 10M | 475M | 486M | 391M |
| EPS | $-2.91 | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
| Free Cash Flow | 518M | 518M | 502M | 365M | 295M | 532M |
| ROIC | 0.4% | 0.5% | 2.4% | 8.3% | 9.2% | 11.3% |
| Gross Margin | 42.4% | 42.4% | 42.1% | 44.4% | 46.1% | 48.1% |
| Debt/Equity | 0.81 | 0.81 | 0.79 | 0.85 | 1.04 | 1.15 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 25M | 25M | 227M | 617M | 651M | 590M |
| Operating Margin | 0.6% | 0.6% | 5.6% | 14.9% | 16.4% | 16.7% |
| ROE | -4.6% | -4.4% | 0.3% | 13.2% | 16.3% | 16.8% |
| Shares Outstanding | 50M | 50M | 51M | 51M | 51M | 51M |
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. passes 3 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 16.9x vs a median of 22.4x. The company's 5-year average ROIC is 6.3% with a gross margin of 44.6%. Total shareholder yield (buybacks) is 4.1%. At current prices, the estimated annualized return to fair value is +6.1%.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) has a 5-year average return on invested capital (ROIC) of 6.3%. This is below average and may indicate limited pricing power.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) has a market capitalization of $8.8B. It is classified as a mid-cap stock.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 4.08%.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) operates in the Services-Commercial Physical & Biological Research industry, within the Industrials sector.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported annual revenue of $4.0 billion in its most recent fiscal year, based on SEC EDGAR filings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) has a net profit margin of -3.6%. The company is currently unprofitable.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) generated $518 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) has a debt-to-equity ratio of 0.81. This indicates moderate leverage.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported earnings per share (EPS) of $-2.91 in its most recent fiscal year.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) has a return on equity (ROE) of -4.4%. A negative ROE may indicate losses or negative equity.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) has a 5-year average gross margin of 44.6%. This indicates decent pricing power.
The Ledger Terminal provides 18 years of financial data for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) has a book value per share of $63.80, based on its most recent annual SEC filing.